Abstract:Ethnopharmacological relevance: Chronic pain management represents a serious healthcare problem worldwide. The use of opioid analgesics for pain has always been hampered by their side effects; in particular, the addictive liability associated with chronic use. Finding a morphine replacement has been a long-standing goal in the field of analgesia. In traditional Chinese medicine, processed Buthus martensii Karsch (BmK) scorpion has been used as a painkiller to treat chronic inflammatory arthritis and spondylitis, so called "Scorpio-analgesia". However, the molecular basis and the underline mechanism for the Scorpio-analgesia are still unclear. Aim of the study: The study aims to investigate the molecular basis of "Scorpio analgesia" and identify novel analgesics from BmK scorpion. Materials and methods: In this study, the analgesic abilities were determined using formalin-, acetic acid-and complete Freund's adjuvant-induced pain models. The effect of BmK venom and processed BmK venom on Nav1.7 were detected by whole-cell voltage-clamp recordings on HEK293-hNav1.7 stable cell line. Action potentials in Dorsal root ganglion (DRG) neurons induced by Makatoxin-3-R58A were recorded in current-clamp mode. The content of Makatoxin-3 was detected using competitive enzyme-linked immunosorbent assay based on the Makatoxin-3 antibody. High performance liquid chromatography, western blot and circular dichroism spectroscopy were used to analysis the stability of Makatoxin-3. Results: Here we demonstrate that Makatoxin-3, an alpha-like toxin in BmK scorpion venom targeting Nav1.7 is the critical component in Scorpio-analgesia. The analgesic effect of Makatoxin-3 could not be reversed by naloxone and is more potent than Nav1.7-selective inhibitors and non-steroidal anti-inflammatory drugs in inflammatory models. Moreover, a R58A mutant of Makatoxin-3 is capable of eliciting analgesia effect without inducing pain response. Conclusions: This study advances ion channel biology and proposes Nav1.7 agonists, rather than the presumed Nav1.7-only blockers, for non-narcotic relief of chronic pain.

Tetrodotoxin -- a Promising Drug to Relieve Cancer Pain

Tetrodotoxin: A New Strategy to Treat Visceral Pain?

A Centipede Toxin Causes Rapid Desensitization of Nociceptor TRPV1 Ion Channel.

Action Mechanism and Side Effects of Tetrodotoxin

Makatoxin-3, a Thermostable Nav1.7 Agonist from Buthus Martensii Karsch (bmk) Scorpion Elicits Non-Narcotic Analgesia in Inflammatory Pain Models.

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

Preparation of Tetrodotoxin Extracellular Nanoparticles and Its Long-Term Local Anesthesia

Targeting TRPV4 Channels for Cancer Pain Relief

Resiniferatoxin: The Evolution of the “Molecular Scalpel” for Chronic Pain Relief

Functional Upregulation of Nav1.8 Sodium Channels on the Membrane of Dorsal Root Ganglia Neurons Contributes to the Development of Cancer-Induced Bone Pain

Tetrodotoxin reduces cue-induced drug craving and anxiety in abstinent heroin addicts

Acute Toxic Effects of Tetrodotoxin in Mice via Intramuscular Injection and Oral Gavage

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

A novel conotoxin from Conus striatus, μ-SIIIA, selectively blocking rat tetrodotoxin-resistant sodium channels

Transient Receptor Potential Channel and Interleukin-17A Involvement in LTTL Gel Inhibition of Bone Cancer Pain in a Rat Model

The road to evolution of ProTx2: how to be a subtype-specific inhibition of human Nav1.7

Resiniferatoxin: Nature's Precision Medicine to Silence TRPV1-Positive Afferents

A Novel Toxin from Haplopelma lividum Selectively Inhibits the NaV1.8 Channel and Possesses Potent Analgesic Efficacy

Contribution of TRESK two-pore domain potassium channel to bone cancer-induced spontaneous pain and evoked cutaneous pain in rats

Targeting A-type K(+) Channels in Primary Sensory Neurons for Bone Cancer Pain in a Rat Model.

A Traditional Chinese Medicine Xiao-Ai-Tong Suppresses Pain through Modulation of Cytokines and Prevents Adverse Reactions of Morphine Treatment in Bone Cancer Pain Patients